Adebrelimab Solution | CAS 2247114-85-6 | High-Purity PD-1 Monoclonal Antibody for Research

Description Contents hide 1 Product Description 2 Product Specifications 3 Mechanism of Action 3.1 1. PD-1/PD-L1 Blockade 3.2 2. T-cell Activation and Functional Enhancement 3.3 3. Modulation of the Tumor Microenvironment 3.4 4. Molecular Signaling Pathways 3.5 5. Preclinical and Experimental Applications 3.6 6. Summary 4 Applications 4.1 1. In Vitro T-Cell Functional Studies 4.2 2. Co-Culture and Tumor Microenvironment Modeling 4.3 3. In Vivo Preclinical Tumor Models 4.4 4. High-Throughput Screening Applications 4.5 5. Molecular Immunology and Mechanistic Studies 4.6 6. Summary 5 Side Effects 5.1 1. Cellular Effects 5.2 2. Molecular and Signaling Effects 5.3 3. Laboratory Handling Considerations 5.4 4. Off-Target and Experimental Considerations 5.5 5. Summary 6 Keywords 7 Shipping Guarantee 8 Trade Assurance 9 Payment Support 10 Disclaimer 11 References Product DescriptionAdebrelimab Solution (CAS 2247114-85-6) is a fully humanized PD-1 monoclonal antibody formulated for laboratory and preclinical research applications. PD-1 (programmed cell death protein 1) is an inhibitory receptor expressed on activated T-cells that negatively regulates immune responses. By binding to PD-1, Adebrelimab blocks its interaction with PD-L1 and PD-L2, thereby restoring T-cell activity and promoting anti-tumor immune responses.The solution is produced under GMP conditions and undergoes rigorous quality control to ensure high-purity (>99%), structural integrity, and functional consistency. Each batch is validated through ELISA, flow cytometry, and functional T-cell assays, confirming the ability to block PD-1/PD-L1 interactions effectively.Applications in Preclinical Research:Immune checkpoint blockade studies in tumor-infiltrating lymphocytes (TILs) and peripheral T-cells.Evaluation of T-cell proliferation, cytokine secretion (IFN-γ, IL-2), and cytotoxic activity.In vivo preclinical tumor models assessing anti-tumor efficacy, immune cell infiltration, and combination immunotherapy strategies.Investigation of molecular mechanisms underlying PD-1-mediated immune suppression and T-cell exhaustion.Mechanistic Research:PD-1/PD-L1 Interaction Inhibition: Blocks PD-1 engagement, restoring T-cell signaling pathways.T-cell Activation: Induces proliferation and cytokine production in effector T-cells.Immune Modulation: Alters tumor microenvironment by enhancing T-cell infiltration and cytotoxic activity.Quality and Stability:Adebrelimab Solution is formulated for long-term storage at 2–8°C with stabilizers to maintain protein conformation and functional activity. The solution is supplied in sterile, ready-to-use format for precise dosing in in vitro and in vivo experiments.Experimental Use:Researchers utilize Adebrelimab Solution to explore immune checkpoint biology, study anti-tumor immune responses, test combination immunotherapies, and investigate biomarkers of T-cell activation. Its high-purity, consistent activity, and ease of use make it an ideal tool for preclinical immuno-oncology research, mechanistic studies, and translational applications.By providing a reproducible, high-purity monoclonal antibody in solution form, Adebrelimab Solution enables laboratories to conduct detailed investigations of PD-1-mediated immune regulation, T-cell responses, and tumor immunotherapy mechanisms with confidence in experimental reproducibility and biological relevance.Product SpecificationsParameterSpecificationChemical Name / SynonymsAdebrelimab, PD-1 monoclonal antibody, SHR-1316CAS Number2247114-85-6Molecular FormulaNot applicable (monoclonal antibody)Molecular Weight~150 kDaPurity≥99% (ELISA/SEC-HPLC)AppearanceClear, colorless to light yellow sterile solutionDosage FormSolutionSolubilityFully soluble in aqueous buffers; ready-to-use for cell culture and in vivo studiesConcentrationTypically provided at 10 mg/mL or as specified for research applicationsStorage Temperature2–8°C, avoid freeze-thaw cyclesStabilityStable for ≥12 months under recommended storage conditionsAnalytical MethodsELISA, flow cytometry, SEC-HPLC, SDS-PAGE, functional T-cell assaysMechanistic TargetProgrammed cell death protein 1 (PD-1)Structural CategoryFully human IgG4 monoclonal antibodyApplicationsImmune checkpoint blockade research, T-cell activation studies, tumor immunotherapy modeling, biomarker analysisBatch ConsistencyGMP-compliant production with consistent binding affinity and biological activityRegulatory NotesFor research use only; not for human or veterinary useOriginChina, GMP-certified facilityAdditional DataCoA provided for each batch; functional blocking assays verified; endotoxin levels <0.1 EU/mLDetailed Description:Adebrelimab Solution is supplied in a sterile, ready-to-use format suitable for in vitro and in vivo applications. The solution ensures high-purity, functional integrity, and reproducible PD-1 blockade across experimental setups. Researchers can use the solution for immune checkpoint studies, T-cell functional assays, tumor microenvironment modeling, and combination immunotherapy experiments.GMP production guarantees batch-to-batch consistency, allowing multi-center studies and preclinical projects to maintain reproducibility. Each batch is validated through ELISA, flow cytometry, and functional T-cell assays to confirm PD-1 binding and checkpoint inhibition activity, ensuring reliable mechanistic research outcomes.The solution format reduces handling errors and allows precise dosing for T-cell proliferation assays, cytokine secretion analysis, and tumor model studies, making Adebrelimab Solution an essential tool for mechanistic immuno-oncology research and translational studies.Mechanism of ActionAdebrelimab Solution (CAS 2247114-85-6) is a fully humanized PD-1 monoclonal antibody that functions by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. PD-1 is an immune checkpoint receptor expressed on activated T-cells, B-cells, and some myeloid cells. Engagement of PD-1 with its ligands suppresses T-cell receptor (TCR) signaling, leading to T-cell exhaustion, reduced proliferation, and diminished cytokine production. By binding PD-1, Adebrelimab restores T-cell effector functions, promoting immune-mediated tumor cell clearance in preclinical research settings.1. PD-1/PD-L1 BlockadeUpon administration in vitro or in vivo, Adebrelimab Solution binds selectively to PD-1 on the surface of T-cells, effectively preventing PD-L1 and PD-L2 from engaging PD-1. This blockade lifts inhibitory signaling pathways and restores downstream TCR-mediated activation. Researchers observe:Enhanced T-cell proliferationIncreased cytokine production (e.g., IFN-γ, IL-2, TNF-α)Augmented cytotoxic activity against tumor cellsThe high-purity and consistent formulation of Adebrelimab Capsules ensures reproducible binding kinetics and functional effects across experimental models.2. T-cell Activation and Functional EnhancementAdebrelimab Solution modulates multiple intracellular pathways to restore T-cell effector function:PI3K/Akt signaling: Enhances metabolic activity and survival in activated T-cells.MAPK/ERK pathway: Promotes proliferation and gene transcription for cytokine production.NFAT/NF-κB transcriptional activation: Drives expression of pro-inflammatory and cytotoxic genes.In preclinical experiments, researchers can measure functional endpoints such as cytotoxic degranulation, IFN-γ secretion, and proliferation to quantify the effects of Adebrelimab Solution on T-cell activation.3. Modulation of the Tumor MicroenvironmentBy blocking PD-1, Adebrelimab indirectly remodels the tumor microenvironment (TME) in experimental models:Increased infiltration of CD8 cytotoxic T lymphocytes (CTLs)Reduction of T-cell exhaustion markers (e.g., TIM-3, LAG-3)Enhanced antigen presentation and dendritic cell activationSuppression of immunosuppressive myeloid populationsThese effects allow researchers to investigate the mechanistic basis of immune checkpoint inhibition, identify biomarkers, and study the synergy of combination immunotherapies in preclinical tumor models.4. Molecular Signaling PathwaysAdebrelimab Solution influences multiple molecular pathways critical for T-cell activation:JAK/STAT signaling: Facilitates transcription of effector cytokines and promotes anti-tumor responses.Checkpoint inhibitory pathway downregulation: Reduces expression of PD-1-induced suppressive genes.Apoptosis modulation in tumor cells: Secondary effect mediated by enhanced CTL cytotoxicity.These pathways are measurable in laboratory assays, including flow cytometry, western blotting, ELISA, and transcriptional profiling, enabling detailed mechanistic studies of PD-1 blockade.5. Preclinical and Experimental ApplicationsAdebrelimab Solution is widely applied in preclinical immuno-oncology research, including:In vitro T-cell functional assays: Proliferation, cytokine secretion, and cytotoxicity studies.Co-culture models: Studying interactions between tumor cells and immune cells.In vivo tumor models: Assessment of tumor growth inhibition, immune infiltration, and combination therapy efficacy.Biomarker discovery: Identifying predictive markers of PD-1 responsiveness and T-cell activation states.The solution formulation ensures reproducibility, precise dosing, and minimal handling variability, making it ideal for mechanistic research and translational studies.6. SummaryIn summary, Adebrelimab Solution (CAS 2247114-85-6) acts as a high-purity PD-1 monoclonal antibody that blocks inhibitory signaling, restores T-cell activity, and promotes anti-tumor immune responses in preclinical research. Its consistent formulation, verified binding activity, and functional efficacy make it a reliable tool for mechanistic studies of immune checkpoint biology, T-cell activation, and combination immunotherapy research.Adebrelimab SolutionApplicationsAdebrelimab Solution (CAS 2247114-85-6) is a versatile tool for preclinical immuno-oncology research, enabling comprehensive studies of PD-1 checkpoint blockade, T-cell activation, and tumor immune modulation. Its high-purity, sterile solution format allows reproducible dosing in diverse experimental settings, including in vitro assays, ex vivo studies, and in vivo preclinical models.1. In Vitro T-Cell Functional StudiesResearchers utilize Adebrelimab Solution in cell culture systems to investigate T-cell responses:Proliferation assays: Measures the expansion of activated T-cells in response to antigen stimulation with PD-1 blockade.Cytokine secretion analysis: Quantifies IFN-γ, IL-2, and TNF-α production using ELISA or flow cytometry.Cytotoxicity evaluation: Assesses the ability of T-cells to induce apoptosis in tumor target cells.These studies allow laboratories to model immune checkpoint inhibition, validate mechanistic pathways, and identify experimental parameters for translational research.2. Co-Culture and Tumor Microenvironment ModelingAdebrelimab Solution is used in co-culture systems combining tumor cells, immune cells, and stromal components:Tumor-infiltrating lymphocyte (TIL) studies: Investigate T-cell activation, exhaustion, and cytotoxic function.Immune cell-tumor cell interactions: Analyze checkpoint-mediated suppression and reversal mechanisms.Biomarker identification: Study expression of PD-L1, CTLA-4, TIM-3, and other inhibitory receptors in the TME.These models provide a platform for mechanistic immunology research and testing novel combination therapies in preclinical studies.3. In Vivo Preclinical Tumor ModelsIn animal studies, Adebrelimab Solution facilitates:Tumor growth inhibition studies: Evaluation of checkpoint blockade efficacy in xenograft and syngeneic models.Immune infiltration analysis: Quantification of CD8 , CD4 , and regulatory T-cells within tumors.Combination immunotherapy research: Testing PD-1 blockade alongside chemotherapy, radiation, or other immunomodulators.These experiments provide critical insight into the mechanistic basis of immune checkpoint inhibition and the therapeutic potential of Adebrelimab Solution.4. High-Throughput Screening ApplicationsThe solution format of Adebrelimab is compatible with high-throughput screening (HTS) assays:Screening for small molecules, antibodies, or biologics that synergize with PD-1 blockade.Multi-well plate-based T-cell functional assays for rapid evaluation of immunomodulatory effects.Quantitative analysis of dose-response and checkpoint inhibition dynamics.This enables laboratories to identify novel combinatorial strategies and accelerate translational research.5. Molecular Immunology and Mechanistic StudiesAdebrelimab Solution allows detailed investigation of molecular pathways affected by PD-1 inhibition:Signal transduction studies: PI3K/Akt, MAPK/ERK, JAK/STAT pathways in T-cells.Gene expression profiling: Assessment of effector cytokines, exhaustion markers, and checkpoint-related genes.Functional assays: Flow cytometry, ELISPOT, and intracellular cytokine staining for mechanistic validation.Researchers can elucidate immune response modulation, study checkpoint pathways, and explore biomarker-driven experiments using this high-purity antibody solution.6. SummaryIn summary, Adebrelimab Solution (CAS 2247114-85-6) provides a comprehensive platform for preclinical and mechanistic immuno-oncology research. Its applications include:T-cell functional assays and cytotoxicity studiesCo-culture models and tumor microenvironment analysisIn vivo tumor growth inhibition and immune infiltration studiesHigh-throughput screening for combination therapiesMolecular immunology and biomarker explorationThe high-purity, sterile solution formulation ensures reproducible experimental results across in vitro, ex vivo, and in vivo research applications, making Adebrelimab Solution an indispensable tool in modern immuno-oncology research.Side EffectsAdebrelimab Solution (CAS 2247114-85-6), although designed exclusively for preclinical and laboratory research, exhibits measurable biological effects that are critical for investigators to consider when designing experiments. As a PD-1 monoclonal antibody, the solution modulates T-cell activity and immune checkpoint pathways, leading to intended mechanistic outcomes alongside observable laboratory phenomena.1. Cellular EffectsExposure to Adebrelimab Solution enhances T-cell proliferation and cytotoxic activity in vitro. Activated T-cells display increased cytokine secretion (IFN-γ, IL-2) and upregulated expression of activation markers such as CD69 and CD25. In co-culture with tumor cells, T-cell-mediated apoptosis of target cells is significantly elevated, reflecting the functional reversal of PD-1-mediated inhibition. These cellular effects are dose-dependent and provide reproducible endpoints for mechanistic immunology research.2. Molecular and Signaling EffectsAt the molecular level, Adebrelimab blocks PD-1/PD-L1 interaction, resulting in the activation of multiple intracellular signaling pathways:PI3K/Akt pathway: Promotes T-cell survival and metabolic fitness.MAPK/ERK pathway: Enhances proliferation and effector functions.JAK/STAT signaling: Supports transcription of pro-inflammatory cytokines and cytotoxic genes.NFAT and NF-κB activation: Drives gene expression critical for immune responses.These pathways are measurable through flow cytometry, western blotting, and ELISA, allowing researchers to quantify the immunomodulatory effects of Adebrelimab Solution in a controlled setting.3. Laboratory Handling ConsiderationsAlthough formulated as a sterile solution, Adebrelimab is a bioactive monoclonal antibody and should be handled using standard laboratory biosafety precautions:Personal Protective Equipment (PPE): Gloves, lab coat, eye protectionUse of biosafety cabinets or fume hoods for preparationAvoidance of contamination and repeated freeze-thaw cycles to preserve activityProper disposal of residual antibody and contaminated consumables to maintain GLP complianceAdhering to these procedures ensures both experimental reproducibility and laboratory safety.4. Off-Target and Experimental ConsiderationsHigh concentrations of Adebrelimab Solution may cause non-specific T-cell activation or unintended modulation of co-stimulatory pathways. Researchers should carefully titrate antibody concentrations, validate effects with appropriate controls, and confirm specificity through complementary assays such as PD-1 knockout or isotype control experiments. Understanding these parameters prevents confounding effects in mechanistic studies and ensures reliable interpretation of experimental data.5. SummaryIn preclinical research, Adebrelimab Solution induces T-cell proliferation, cytokine secretion, and enhanced cytotoxic activity, consistent with its mechanism as a PD-1 inhibitor. Awareness of cellular and molecular effects, along with proper laboratory handling, enables researchers to design robust, reproducible experiments while ensuring safety. These characteristics make Adebrelimab Solution (CAS 2247114-85-6) an essential tool for mechanistic immunology studies, immune checkpoint research, and preclinical tumor immunotherapy experiments.KeywordsAdebrelimab Solution, CAS 2247114-85-6, PD-1 monoclonal antibody, immune checkpoint inhibitor, T-cell activation reagent, preclinical immuno-oncology research, tumor immunotherapy research, high-purity antibody, sterile research solution, mechanistic immunology tool, immune modulation study, combinatorial therapy research, bulk production research-grade antibody, factory small-molecule supplier, China antibody manufacturer, high-purity research reagent, translational immunology tool.Shipping GuaranteeAdebrelimab Solution (CAS 2247114-85-6) is shipped under strict cold-chain conditions to maintain structural integrity and biological activity. Packaging is insulated and tamper-evident, with real-time tracking and insurance for all shipments. International delivery, express services, and temperature-sensitive handling options ensure that the solution reaches laboratories in optimal condition for preclinical and mechanistic studies.Trade AssuranceAll batches of Adebrelimab Solution are manufactured under GMP-compliant standards with purity ≥99%, confirmed via ELISA, flow cytometry, and SEC-HPLC. Certificates of Analysis (CoA) are provided for each lot. Bulk production, OEM, and customized concentrations are available to meet research requirements, with reliable replacement or return policies ensuring consistent experimental reproducibility.Payment SupportFlexible and secure payment methods include PayPal, major credit cards, T/T bank transfer, USDT, Bitcoin, and Ethereum. Transactions are fully encrypted to protect sensitive financial information, enabling global research laboratories to efficiently procure high-purity Adebrelimab Solution for preclinical studies, mechanistic experiments, and translational research.DisclaimerAdebrelimab Solution (CAS 2247114-85-6) is intended strictly for laboratory and preclinical research use. It is not for human or veterinary administration. Users must follow institutional biosafety guidelines, utilize appropriate PPE, and handle the antibody according to GLP standards. Improper use may affect immune responses and experimental outcomes. All information is provided solely for scientific research and educational applications.ReferencesPubChem – AdebrelimabProvides chemical structure, molecular properties, and bioactivity information for Adebrelimab Solution, supporting preclinical immuno-oncology research.ChEMBL – AdebrelimabContains detailed bioactivity data, molecular target interactions, and experimental assay results suitable for mechanistic studies of PD-1 blockade.DrugBank – AdebrelimabOffers pharmacological profiles, mechanism of action insights, and preclinical research applications of Adebrelimab Solution.PubMed – Adebrelimab Research ArticlesAccess peer-reviewed publications detailing PD-1 inhibition, T-cell activation, immune checkpoint studies, and preclinical tumor immunotherapy research.IUPHAR/BPS – Immune Checkpoint TargetsProvides curated data on molecular targets, signaling pathways, and immune checkpoint mechanisms relevant to Adebrelimab Solution research.Additional ResourcesACS Chemical Biology Journal Articles on Monoclonal Antibodies.Sigma-Aldrich Technical Datasheets.ResearchGate Experimental Studies on PD-1 Blockade.These references provide authoritative, peer-reviewed information for laboratories using Adebrelimab Solution (CAS 2247114-85-6) in mechanistic, preclinical, and translational research applications. Researchers can access molecular data, functional assay protocols, and experimental guidelines to ensure reproducible and high-impact studies.